Stem definition | Drug id | CAS RN |
---|---|---|
atropine derivatives | 333 | 86-13-5 |
Dose | Unit | Route |
---|---|---|
2 | mg | O |
2 | mg | P |
Property | Value | Reference |
---|---|---|
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.21 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Hosey CM, Chan R, Benet LZ |
BA (Bioavailability) | 29 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
March 5, 1954 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Granulocytopenia | 344.12 | 18.05 | 96 | 9452 | 5464 | 53334054 |
Completed suicide | 291.97 | 18.05 | 222 | 9326 | 137979 | 53201539 |
Tardive dyskinesia | 180.29 | 18.05 | 64 | 9484 | 8006 | 53331512 |
Schizophrenia | 175.94 | 18.05 | 67 | 9481 | 10212 | 53329306 |
Psychotic disorder | 160.27 | 18.05 | 81 | 9467 | 24304 | 53315214 |
Toxicity to various agents | 128.15 | 18.05 | 176 | 9372 | 219422 | 53120096 |
Neuroleptic malignant syndrome | 125.51 | 18.05 | 55 | 9493 | 11978 | 53327540 |
Extrapyramidal disorder | 114.35 | 18.05 | 52 | 9496 | 12350 | 53327168 |
Paranoia | 108.82 | 18.05 | 49 | 9499 | 11375 | 53328143 |
Hallucination, auditory | 107.40 | 18.05 | 49 | 9499 | 11724 | 53327794 |
Sedation | 72.06 | 18.05 | 52 | 9496 | 29623 | 53309895 |
Dystonia | 67.69 | 18.05 | 37 | 9511 | 12984 | 53326534 |
Oculogyric crisis | 66.66 | 18.05 | 20 | 9528 | 1468 | 53338050 |
Agitation | 66.03 | 18.05 | 66 | 9482 | 58560 | 53280958 |
Muscle rigidity | 65.36 | 18.05 | 34 | 9514 | 10807 | 53328711 |
Blood prolactin increased | 58.60 | 18.05 | 22 | 9526 | 3217 | 53336301 |
Tremor | 54.73 | 18.05 | 88 | 9460 | 125648 | 53213870 |
Catatonia | 53.88 | 18.05 | 22 | 9526 | 4018 | 53335500 |
Schizoaffective disorder | 51.40 | 18.05 | 18 | 9530 | 2159 | 53337359 |
Ileus paralytic | 51.08 | 18.05 | 22 | 9526 | 4589 | 53334929 |
Suicidal ideation | 50.28 | 18.05 | 58 | 9490 | 60453 | 53279065 |
Dyskinesia | 49.68 | 18.05 | 43 | 9505 | 31790 | 53307728 |
Clonus | 49.27 | 18.05 | 21 | 9527 | 4270 | 53335248 |
Aggression | 47.85 | 18.05 | 37 | 9511 | 23366 | 53316152 |
Akathisia | 46.34 | 18.05 | 25 | 9523 | 8546 | 53330972 |
Delusion | 46.06 | 18.05 | 28 | 9520 | 11981 | 53327537 |
Leukopenia | 45.88 | 18.05 | 61 | 9487 | 73402 | 53266116 |
Hyperreflexia | 44.35 | 18.05 | 21 | 9527 | 5459 | 53334059 |
Myocarditis | 43.84 | 18.05 | 24 | 9524 | 8444 | 53331074 |
Drooling | 43.05 | 18.05 | 18 | 9530 | 3490 | 53336028 |
Galactorrhoea | 40.80 | 18.05 | 18 | 9530 | 3977 | 53335541 |
Cardiac arrest | 37.28 | 18.05 | 63 | 9485 | 93604 | 53245914 |
Abnormal behaviour | 37.11 | 18.05 | 31 | 9517 | 21835 | 53317683 |
Salivary hypersecretion | 36.83 | 18.05 | 20 | 9528 | 6923 | 53332595 |
Treatment noncompliance | 36.82 | 18.05 | 37 | 9511 | 32998 | 53306520 |
Amaurosis | 36.35 | 18.05 | 10 | 9538 | 538 | 53338980 |
Hyperthermia | 35.51 | 18.05 | 21 | 9527 | 8548 | 53330970 |
Confusional state | 34.46 | 18.05 | 94 | 9454 | 194127 | 53145391 |
Haemoglobin urine | 33.53 | 18.05 | 7 | 9541 | 113 | 53339405 |
Drug interaction | 32.96 | 18.05 | 100 | 9448 | 219229 | 53120289 |
Hallucination | 32.52 | 18.05 | 44 | 9504 | 53794 | 53285724 |
Encephalitis autoimmune | 31.69 | 18.05 | 11 | 9537 | 1285 | 53338233 |
Joint swelling | 31.16 | 18.05 | 3 | 9545 | 234635 | 53104883 |
Mydriasis | 30.14 | 18.05 | 21 | 9527 | 11305 | 53328213 |
Amenorrhoea | 28.85 | 18.05 | 19 | 9529 | 9330 | 53330188 |
Arthralgia | 28.84 | 18.05 | 22 | 9526 | 439761 | 52899757 |
Torsade de pointes | 27.54 | 18.05 | 21 | 9527 | 12984 | 53326534 |
Psychiatric decompensation | 27.39 | 18.05 | 10 | 9538 | 1352 | 53338166 |
Dysarthria | 27.35 | 18.05 | 35 | 9513 | 40533 | 53298985 |
Parkinsonism | 27.05 | 18.05 | 18 | 9530 | 8995 | 53330523 |
Cardio-respiratory arrest | 26.73 | 18.05 | 42 | 9506 | 58716 | 53280802 |
Electrocardiogram QT prolonged | 26.61 | 18.05 | 41 | 9507 | 56362 | 53283156 |
Toxic encephalopathy | 25.81 | 18.05 | 15 | 9533 | 5912 | 53333606 |
Diabetes mellitus | 25.17 | 18.05 | 39 | 9509 | 53860 | 53285658 |
Mental disorder | 24.80 | 18.05 | 26 | 9522 | 24350 | 53315168 |
Hyperprolactinaemia | 24.68 | 18.05 | 12 | 9536 | 3303 | 53336215 |
Cognitive disorder | 24.65 | 18.05 | 35 | 9513 | 44743 | 53294775 |
Suspected suicide | 24.34 | 18.05 | 13 | 9535 | 4355 | 53335163 |
Lipids decreased | 24.29 | 18.05 | 4 | 9544 | 15 | 53339503 |
Facial paralysis | 24.07 | 18.05 | 20 | 9528 | 13973 | 53325545 |
Red blood cells urine | 23.95 | 18.05 | 7 | 9541 | 469 | 53339049 |
Diarrhoea | 22.68 | 18.05 | 49 | 9499 | 625497 | 52714021 |
Eosinophil count abnormal | 22.55 | 18.05 | 7 | 9541 | 576 | 53338942 |
Mental status changes | 21.88 | 18.05 | 31 | 9517 | 39540 | 53299978 |
Restlessness | 21.78 | 18.05 | 26 | 9522 | 28061 | 53311457 |
Schizoaffective disorder bipolar type | 21.47 | 18.05 | 5 | 9543 | 136 | 53339382 |
Hypersensitivity | 20.73 | 18.05 | 6 | 9542 | 210659 | 53128859 |
Pain | 20.57 | 18.05 | 47 | 9501 | 588351 | 52751167 |
Mania | 20.54 | 18.05 | 17 | 9531 | 11812 | 53327706 |
Abdominal discomfort | 20.50 | 18.05 | 7 | 9541 | 221055 | 53118463 |
Flat affect | 19.93 | 18.05 | 8 | 9540 | 1397 | 53338121 |
Bipolar disorder | 19.87 | 18.05 | 14 | 9534 | 7672 | 53331846 |
Areflexia | 19.67 | 18.05 | 10 | 9538 | 3026 | 53336492 |
Pneumonia aspiration | 19.15 | 18.05 | 27 | 9521 | 34274 | 53305244 |
Screaming | 18.95 | 18.05 | 10 | 9538 | 3267 | 53336251 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Granulocytopenia | 529.11 | 18.88 | 161 | 11125 | 6354 | 32495886 |
Completed suicide | 219.76 | 18.88 | 211 | 11075 | 92306 | 32409934 |
Tardive dyskinesia | 183.86 | 18.88 | 70 | 11216 | 5461 | 32496779 |
Neuroleptic malignant syndrome | 172.68 | 18.88 | 95 | 11191 | 17400 | 32484840 |
Extrapyramidal disorder | 158.54 | 18.88 | 79 | 11207 | 11816 | 32490424 |
Myocarditis | 154.55 | 18.88 | 77 | 11209 | 11513 | 32490727 |
Psychotic disorder | 146.03 | 18.88 | 94 | 11192 | 22926 | 32479314 |
Toxicity to various agents | 130.04 | 18.88 | 226 | 11060 | 177815 | 32324425 |
Schizophrenia | 123.34 | 18.88 | 63 | 11223 | 9921 | 32492319 |
Agitation | 98.48 | 18.88 | 110 | 11176 | 57126 | 32445114 |
Hallucination, auditory | 96.05 | 18.88 | 54 | 11232 | 10296 | 32491944 |
Dystonia | 94.74 | 18.88 | 54 | 11232 | 10569 | 32491671 |
Akathisia | 85.80 | 18.88 | 44 | 11242 | 6981 | 32495259 |
Tremor | 77.99 | 18.88 | 117 | 11169 | 81160 | 32421080 |
Sedation | 71.74 | 18.88 | 56 | 11230 | 18470 | 32483770 |
Cogwheel rigidity | 70.96 | 18.88 | 24 | 11262 | 1326 | 32500914 |
Drooling | 69.17 | 18.88 | 30 | 11256 | 3267 | 32498973 |
Galactorrhoea | 65.18 | 18.88 | 17 | 11269 | 376 | 32501864 |
Dystonic tremor | 65.06 | 18.88 | 15 | 11271 | 194 | 32502046 |
Device leakage | 62.35 | 18.88 | 31 | 11255 | 4605 | 32497635 |
Abnormal behaviour | 60.02 | 18.88 | 59 | 11227 | 26407 | 32475833 |
Hyperprolactinaemia | 59.83 | 18.88 | 21 | 11265 | 1297 | 32500943 |
Leukopenia | 58.27 | 18.88 | 87 | 11199 | 60035 | 32442205 |
Muscle rigidity | 54.91 | 18.88 | 39 | 11247 | 11147 | 32491093 |
Paranoia | 53.82 | 18.88 | 38 | 11248 | 10761 | 32491479 |
Treatment noncompliance | 53.23 | 18.88 | 56 | 11230 | 27146 | 32475094 |
Drug abuse | 52.10 | 18.88 | 97 | 11189 | 80146 | 32422094 |
Aggression | 51.70 | 18.88 | 66 | 11220 | 39323 | 32462917 |
Syringe issue | 50.46 | 18.88 | 25 | 11261 | 3686 | 32498554 |
Parkinsonism | 49.52 | 18.88 | 32 | 11254 | 7837 | 32494403 |
Schizoaffective disorder | 48.71 | 18.88 | 18 | 11268 | 1290 | 32500950 |
Anticholinergic syndrome | 47.30 | 18.88 | 16 | 11270 | 884 | 32501356 |
Restlessness | 44.76 | 18.88 | 49 | 11237 | 24832 | 32477408 |
Drug interaction | 44.41 | 18.88 | 171 | 11115 | 218014 | 32284226 |
Product dose omission issue | 44.37 | 18.88 | 105 | 11181 | 102470 | 32399770 |
Inappropriate schedule of product administration | 43.93 | 18.88 | 66 | 11220 | 45759 | 32456481 |
Priapism | 43.49 | 18.88 | 25 | 11261 | 4966 | 32497274 |
Antipsychotic drug level increased | 42.68 | 18.88 | 22 | 11264 | 3524 | 32498716 |
Catatonia | 42.14 | 18.88 | 24 | 11262 | 4684 | 32497556 |
Blood prolactin increased | 38.29 | 18.88 | 16 | 11270 | 1589 | 32500651 |
Delusion | 36.97 | 18.88 | 33 | 11253 | 13075 | 32489165 |
Dyskinesia | 36.54 | 18.88 | 43 | 11243 | 23560 | 32478680 |
Mental status changes | 36.43 | 18.88 | 55 | 11231 | 38282 | 32463958 |
Suicidal ideation | 35.29 | 18.88 | 54 | 11232 | 38029 | 32464211 |
Drug level increased | 35.17 | 18.88 | 39 | 11247 | 20041 | 32482199 |
Agranulocytosis | 35.07 | 18.88 | 42 | 11244 | 23435 | 32478805 |
Eosinophilic pleural effusion | 32.48 | 18.88 | 9 | 11277 | 252 | 32501988 |
Blood creatine phosphokinase increased | 32.05 | 18.88 | 57 | 11229 | 45419 | 32456821 |
Sinus tachycardia | 30.69 | 18.88 | 33 | 11253 | 16381 | 32485859 |
Delirium | 29.50 | 18.88 | 54 | 11232 | 43992 | 32458248 |
Lethargy | 29.47 | 18.88 | 52 | 11234 | 41176 | 32461064 |
Homicidal ideation | 27.64 | 18.88 | 15 | 11271 | 2665 | 32499575 |
Head titubation | 27.47 | 18.88 | 8 | 11278 | 269 | 32501971 |
Musculoskeletal stiffness | 27.39 | 18.88 | 49 | 11237 | 39215 | 32463025 |
Diarrhoea | 26.84 | 18.88 | 54 | 11232 | 364748 | 32137492 |
Blood pH decreased | 26.72 | 18.88 | 14 | 11272 | 2319 | 32499921 |
Mania | 26.67 | 18.88 | 24 | 11262 | 9608 | 32492632 |
Blood triglycerides increased | 26.65 | 18.88 | 29 | 11257 | 14590 | 32487650 |
Oculogyric crisis | 26.51 | 18.88 | 12 | 11274 | 1445 | 32500795 |
Overdose | 26.27 | 18.88 | 78 | 11208 | 86999 | 32415241 |
Febrile neutropenia | 25.98 | 18.88 | 5 | 11281 | 119561 | 32382679 |
Needle issue | 25.47 | 18.88 | 17 | 11269 | 4392 | 32497848 |
Bipolar disorder | 24.86 | 18.88 | 16 | 11270 | 3890 | 32498350 |
Antipsychotic drug level decreased | 24.68 | 18.88 | 10 | 11276 | 918 | 32501322 |
Parasomnia | 24.57 | 18.88 | 8 | 11278 | 392 | 32501848 |
Type 2 diabetes mellitus | 24.07 | 18.88 | 28 | 11258 | 15144 | 32487096 |
Device malfunction | 24 | 18.88 | 22 | 11264 | 9017 | 32493223 |
Weight increased | 23.42 | 18.88 | 73 | 11213 | 83590 | 32418650 |
Haemophagocytic lymphohistiocytosis | 21.56 | 18.88 | 23 | 11263 | 11312 | 32490928 |
Gynaecomastia | 20.61 | 18.88 | 20 | 11266 | 8799 | 32493441 |
Globulins decreased | 20.51 | 18.88 | 6 | 11280 | 205 | 32502035 |
Troponin increased | 20.39 | 18.88 | 21 | 11265 | 9921 | 32492319 |
Salivary hypersecretion | 20.15 | 18.88 | 19 | 11267 | 8069 | 32494171 |
Somnolence | 19.93 | 18.88 | 80 | 11206 | 103717 | 32398523 |
Faecaloma | 19.76 | 18.88 | 15 | 11271 | 4741 | 32497499 |
Source | Code | Description |
---|---|---|
ATC | N04AC01 | NERVOUS SYSTEM ANTI-PARKINSON DRUGS ANTICHOLINERGIC AGENTS Ethers of tropine or tropine derivatives |
FDA MoA | N0000000207 | Histamine Receptor Antagonists |
FDA MoA | N0000175370 | Cholinergic Antagonists |
FDA EPC | N0000175574 | Anticholinergic |
CHEBI has role | CHEBI:48407 | antiparkinson agent |
CHEBI has role | CHEBI:48876 | Antimuskarinika |
CHEBI has role | CHEBI:50370 | parasympatholytics |
CHEBI has role | CHEBI:66956 | antidyskinetic drugs |
CHEBI has role | CHEBI:146270 | oneirogens |
CHEBI has role | CHEBI:149553 | anti-coronaviral agents |
MeSH PA | D018726 | Anti-Dyskinesia Agents |
MeSH PA | D000978 | Antiparkinson Agents |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D018678 | Cholinergic Agents |
MeSH PA | D018680 | Cholinergic Antagonists |
MeSH PA | D015259 | Dopamine Agents |
MeSH PA | D018765 | Dopamine Uptake Inhibitors |
MeSH PA | D049990 | Membrane Transport Modulators |
MeSH PA | D018727 | Muscarinic Antagonists |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D014179 | Neurotransmitter Uptake Inhibitors |
MeSH PA | D010276 | Parasympatholytics |
MeSH PA | D018373 | Peripheral Nervous System Agents |
FDA EPC | N0000175750 | Antihistamine |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Postencephalitic parkinsonism | indication | 19972008 | DOID:14332 |
Parkinsonism | indication | 32798002 | |
Parkinson's disease | indication | 49049000 | DOID:14330 |
Extrapyramidal disease | indication | 76349003 | |
Arteriosclerotic Parkinsonism | indication | ||
Urinary tract obstruction | contraindication | 7163005 | DOID:5200 |
Chronic obstructive lung disease | contraindication | 13645005 | DOID:3083 |
Severe chronic ulcerative colitis | contraindication | 14311001 | |
Disorder of autonomic nervous system | contraindication | 15241006 | |
Toxic megacolon | contraindication | 28536002 | DOID:1770 |
Atony of colon | contraindication | 29479008 | |
Shigellosis | contraindication | 36188001 | |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Conduction disorder of the heart | contraindication | 44808001 | |
Low blood pressure | contraindication | 45007003 | |
Achalasia of esophagus | contraindication | 45564002 | DOID:9164 |
Chronic heart failure | contraindication | 48447003 | |
Dysuria | contraindication | 49650001 | |
Paralytic ileus | contraindication | 55525008 | DOID:8442 |
Ulcerative colitis | contraindication | 64766004 | DOID:8577 |
Hiatal hernia | contraindication | 84089009 | DOID:12642 |
Open-angle glaucoma | contraindication | 84494001 | DOID:1067 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Thyrotoxicosis | contraindication | 90739004 | DOID:7997 |
Myasthenia gravis | contraindication | 91637004 | DOID:437 |
Tardive dyskinesia | contraindication | 102449007 | |
Dysentery | contraindication | 111939009 | |
Gastrointestinal obstruction | contraindication | 126765001 | |
Bleeding | contraindication | 131148009 | |
Gastroesophageal reflux disease | contraindication | 235595009 | DOID:8534 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Benign prostatic hyperplasia | contraindication | 266569009 | |
Retention of urine | contraindication | 267064002 | |
Fever | contraindication | 386661006 | |
Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
Pseudomembranous enterocolitis | contraindication | 397683000 | |
Gastric ulcer | contraindication | 397825006 | DOID:10808 |
Disorder of coronary artery | contraindication | 414024009 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.86 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Muscarinic acetylcholine receptor M1 | GPCR | ANTAGONIST | Ki | 9.64 | WOMBAT-PK | CHEMBL | |||
Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 7.23 | DRUG MATRIX | |||||
Sodium-dependent serotonin transporter | Transporter | IC50 | 4.62 | CHEMBL | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.86 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 8.16 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 6.90 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2C | GPCR | Ki | 7.50 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 6 | GPCR | Ki | 5.89 | DRUG MATRIX | |||||
Alpha-2B adrenergic receptor | GPCR | Ki | 7.52 | DRUG MATRIX | |||||
D(3) dopamine receptor | GPCR | Ki | 6.65 | DRUG MATRIX | |||||
Histamine H1 receptor | GPCR | Ki | 8.96 | WOMBAT-PK | |||||
Histamine H2 receptor | GPCR | Ki | 5.93 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M2 | GPCR | ANTAGONIST | Ki | 8.85 | WOMBAT-PK | ||||
Muscarinic acetylcholine receptor M3 | GPCR | ANTAGONIST | Ki | 8.96 | WOMBAT-PK | ||||
Muscarinic acetylcholine receptor M4 | GPCR | ANTAGONIST | Ki | 8.96 | WOMBAT-PK | ||||
Muscarinic acetylcholine receptor M5 | GPCR | ANTAGONIST | Ki | 8.55 | WOMBAT-PK | ||||
Alpha-2C adrenergic receptor | GPCR | Ki | 7.24 | DRUG MATRIX | |||||
Sodium-dependent dopamine transporter | Transporter | Kd | 7.25 | WOMBAT-PK | |||||
Alpha-1D adrenergic receptor | GPCR | Ki | 7.59 | DRUG MATRIX | |||||
Alpha-2A adrenergic receptor | GPCR | Ki | 6.69 | DRUG MATRIX | |||||
Sodium-dependent neutral amino acid transporter B(0)AT1 | Transporter | INHIBITOR | IC50 | 4.36 | IUPHAR | ||||
Alpha-1B adrenergic receptor | GPCR | Ki | 7.39 | DRUG MATRIX | |||||
Membrane-associated progesterone receptor component 1 | Membrane receptor | Ki | 6.95 | DRUG MATRIX | |||||
Alpha-1A adrenergic receptor | GPCR | IC50 | 6.85 | CHEMBL | |||||
Muscarinic acetylcholine receptor M2 | GPCR | Ki | 8.59 | CHEMBL | |||||
Muscarinic acetylcholine receptor M1 | GPCR | Ki | 9.23 | CHEMBL | |||||
Sodium-dependent serotonin transporter | Transporter | Ki | 5.29 | CHEMBL | |||||
Sodium-dependent dopamine transporter | Transporter | Ki | 6.93 | CHEMBL |
ID | Source |
---|---|
D00778 | KEGG_DRUG |
132-17-2 | SECONDARY_CAS_RN |
1424 | RXNORM |
C0005098 | UMLSCUI |
CHEBI:3048 | CHEBI |
CXQ | PDB_CHEM_ID |
CHEMBL1201203 | ChEMBL_ID |
CHEMBL1200383 | ChEMBL_ID |
DB00245 | DRUGBANK_ID |
7601 | IUPHAR_LIGAND_ID |
292 | INN_ID |
1NHL2J4X8K | UNII |
1201549 | PUBCHEM_CID |
3130 | MMSL |
4264 | MMSL |
563 | MMSL |
d00175 | MMSL |
001647 | NDDF |
004667 | NDDF |
29527005 | SNOMEDCT_US |
372846002 | SNOMEDCT_US |
77390008 | SNOMEDCT_US |
D001590 | MESH_DESCRIPTOR_UI |
4017824 | VANDF |
4019630 | VANDF |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Benztropine Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9233 | INJECTION | 1 mg | INTRAMUSCULAR | ANDA | 15 sections |
Benztropine Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9729 | INJECTION | 1 mg | INTRAMUSCULAR | ANDA | 14 sections |
Benztropine Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0603-2437 | TABLET | 0.50 mg | ORAL | ANDA | 16 sections |
Benztropine Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0603-2438 | TABLET | 1 mg | ORAL | ANDA | 16 sections |
Benztropine Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0603-2439 | TABLET | 2 mg | ORAL | ANDA | 16 sections |
Benztropine Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8210 | TABLET | 0.50 mg | ORAL | ANDA | 16 sections |
Benztropine Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8211 | TABLET | 1 mg | ORAL | ANDA | 16 sections |
benztropine mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8352 | TABLET | 2 mg | ORAL | ANDA | 16 sections |
Benztropine Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-1080 | TABLET | 0.50 mg | ORAL | ANDA | 15 sections |
Benztropine Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-1081 | TABLET | 1 mg | ORAL | ANDA | 15 sections |
Benztropine Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-1082 | TABLET | 2 mg | ORAL | ANDA | 15 sections |
Benztropine Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6788 | TABLET | 0.50 mg | ORAL | ANDA | 16 sections |
Benztropine Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6789 | TABLET | 2 mg | ORAL | ANDA | 16 sections |
Benztropine Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6790 | TABLET | 1 mg | ORAL | ANDA | 16 sections |
Benztropine Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-606 | TABLET | 0.50 mg | ORAL | ANDA | 15 sections |
Benztropine Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-607 | TABLET | 1 mg | ORAL | ANDA | 15 sections |
Benztropine Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-608 | TABLET | 2 mg | ORAL | ANDA | 15 sections |
benztropine mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10858-011 | INJECTION | 1 mg | INTRAMUSCULAR | ANDA | 1 sections |
Benztropine Mesylate Injection, USP | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14789-300 | INJECTION | 1 mg | PARENTERAL | ANDA | 11 sections |
Benztropine Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-012 | INJECTION | 1 mg | INTRAVENOUS | NDA authorized generic | 16 sections |
BENZTROPINE MESYLATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-286 | TABLET | 2 mg | ORAL | ANDA | 15 sections |
Benztropine Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-218 | TABLET | 0.50 mg | ORAL | ANDA | 16 sections |
Benztropine Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-219 | TABLET | 1 mg | ORAL | ANDA | 16 sections |
Benztropine Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-220 | TABLET | 2 mg | ORAL | ANDA | 16 sections |
Benztropine Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-580 | TABLET | 1 mg | ORAL | ANDA | 16 sections |
Benztropine Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-707 | TABLET | 0.50 mg | ORAL | ANDA | 16 sections |
Benztropine Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-796 | TABLET | 1 mg | ORAL | ANDA | 16 sections |
Benztropine Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43353-913 | TABLET | 0.50 mg | ORAL | ANDA | 16 sections |
Benztropine Mesylate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-3116 | TABLET | 1 mg | ORAL | ANDA | 15 sections |
BENZTROPINE MESYLATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-3882 | TABLET | 2 mg | ORAL | ANDA | 13 sections |